RGEN News and Press, Repligen Corporation From 03/22/20

In this episode of  Rule Breaker Investing , Motley Fool co-founder David Gardner shares with you his investment philosophy and how you can use it to beat the market. There are 10 and a half chapters that take you through everything from how to invest in a downturn to how today's science ...

Pessimists are a dime a dozen right now. If you want to make alpha, be contrarian. The easy money already has been made shorting the market. Shorts may well have their Waterloo this week or next. Me, I'm going to look for entry points for upside movement. Yes the S&P closed down hard...

Shares of Repligen  (NASDAQ: RGEN) , a leading provider of proteins and filtration technology that is used to manufacture biologic drugs , rose 10.6% on Friday.  The jump doesn't appear to be caused by any company-specific news. Instead, the double-digit increase was most like...

I made the mistake of looking at the commentary on my last article I was roundly criticized by the ankle biters that I was irresponsible to exhort my readers to not sell. Not only did I have the temerity to question the extent of the damage that the virus will toll on the US (I still do)...

Less than a decade ago, Repligen (NASDAQ: RGEN) was toiling away in clinical trials in an attempt to bring experimental drugs to market. Today, the company's former drug pipeline is a distant memory. It has instead gone all-in on bioprocess engineering products -- the filters, chromatography...

WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, which include...

When is achieving year-over-year growth of 39% for both revenue and operating income not enough? When guidance for the next year disappoints, apparently. Repligen (NASDAQ: RGEN) delivered a solid fourth-quarter and full-year 2019 earnings report yesterday. A combination of new product launc...

Image source: The Motley Fool. Repligen   (NASDAQ: RGEN) Q4 2019 Earnings Call Feb 20, 2020 , 8:30 a.m. ET Operator Continue reading

Repligen Corp. (RGEN) Q4 2019 Earnings Conference Call February 20, 2020, 08:30 ET Company Participants Sondra Newman - Senior Director, IR Anthony Hunt - CEO & President Jon Snodgres - CFO & Secretary Conference Call Participants Daniel Arias - Stifel, Nicolaus &am...

Repligen ( RGEN ) Q4 results : More news on: Repligen Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...